# Incannex Healthcare Inc.: overview
IXHL · Nasdaq · CIK 1873875 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30
Pages: [Overview](/companies/ixhl.md) · [Financials](/companies/ixhl/financials.md) · [Filings](/companies/ixhl/filings.md) · [Insiders](/companies/ixhl/insiders.md)
Latest reported revenue: [$0](/filings/0001628280-26-063506.md) for Q4 FY2025, three months to 2025-06-30, from the 10-K filed Sep 25, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001628280-26-063506).
## Last eight quarters
| Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [74.0](/filings/0001213900-24-098421.md) | [12.0](/filings/0001213900-25-013783.md) | [0.0 d](/filings/0001213900-25-043682.md) | [0.0 d](/filings/0001628280-26-063506.md) | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(8451.4%)](/filings/0001213900-25-110299.md) | [(41700.0%)](/filings/0001213900-26-015867.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [(7324.3%)](/filings/0001213900-26-057227.md) | [(49116.7%)](/filings/0001213900-26-057227.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.29)](/filings/0001213900-25-110299.md) | [(0.33)](/filings/0001213900-26-015867.md) | [(6.19)](/filings/0001213900-26-057227.md) | not reported | [(0.02)](/filings/0001213900-25-110299.md) | [(0.02)](/filings/0001213900-26-015867.md) | [(0.35)](/filings/0001213900-26-057227.md) | not reported |
| Free cash flow | $k | not reported | not reported | [(3,159) d](/filings/0001213900-26-057227.md) | [(1,482) d](/filings/0001628280-26-063506.md) | [(9,165)](/filings/0001213900-25-110299.md) | [(4,626) d](/filings/0001213900-26-015867.md) | [(2,461) d](/filings/0001213900-26-057227.md) | [3,373 d](/filings/0001628280-26-063506.md) |
- Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
## Last five fiscal years
| Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0001213900-24-082937.md) | [0.1](/filings/0001628280-26-063506.md) | [0.0](/filings/0001628280-26-063506.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(250341.7%)](/filings/0001213900-25-092837.md) | [(27661.6%)](/filings/0001628280-26-063506.md) | not reported |
| Net margin | % | not reported | not reported | [(153825.0%)](/filings/0001213900-25-092837.md) | [(54517.4%)](/filings/0001628280-26-063506.md) | not reported |
| Diluted EPS | $ per share | [(1.25)](/filings/0001213900-23-081650.md) | [(3.32)](/filings/0001213900-24-082937.md) | [(1.15)](/filings/0001213900-25-092837.md) | [(40.82)](/filings/0001628280-26-063506.md) | [(1.66)](/filings/0001628280-26-063506.md) |
| Free cash flow | $m | not reported | [(11.1)](/filings/0001213900-24-082937.md) | [(16.1)](/filings/0001213900-25-092837.md) | [(12.5)](/filings/0001628280-26-063506.md) | [(12.9)](/filings/0001628280-26-063506.md) |
- Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare; Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.
## Insider purchases and sales
The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ixhl/insiders.md)
None in coverage.
## Funds that report holding it
From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $557.1k | 148,178 | | Added +77,000 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $358.1k | 95,252 | | New +95,252 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $294.0k | 78,195 | | New +78,195 |
| [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $228.9k | 60,868 | | Added +36,365 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $108.2k | 28,771 | | New +28,771 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $62.0k | 16,500 | Put | New +16,500 |
| [COMMONWEALTH EQUITY SERVICES, LLC](/funds/312272.md) | 2026-06-30 | $52.8k | 14,029 | | Added +1,917 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $38.9k | 10,349 | | New +10,349 |
| [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $24.0k | 6,376 | | Unchanged |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $13.6k | 3,610 | | Reduced −36,759 |
## Recent filings
[All 263 filings](/companies/ixhl/filings.md)
| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-25 | 08:41 ET | [10-K](/filings/0001628280-26-063506.md) | Annual report, period 2026-06-30 | 0001628280-26-063506 |
| 2026-09-09 | 07:30 ET | [8-K](/filings/0001213900-26-098213.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-098213 |
| 2026-08-25 | 07:30 ET | [8-K](/filings/0001213900-26-093244.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-093244 |
| 2026-08-11 | 07:30 ET | [8-K](/filings/0001213900-26-087493.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-087493 |
| 2026-07-23 | 07:30 ET | [8-K](/filings/0001213900-26-080622.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-080622 |
| 2026-06-25 | 07:31 ET | [8-K](/filings/0001213900-26-071745.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-071745 |
| 2026-06-10 | 07:30 ET | [8-K](/filings/0001213900-26-067081.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-067081 |
| 2026-06-09 | 07:30 ET | [8-K](/filings/0001213900-26-066526.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-066526 |
| 2026-05-15 | 09:29 ET | [10-Q](/filings/0001213900-26-057227.md) | Quarterly report, period 2026-03-31 | 0001213900-26-057227 |
| 2026-05-14 | 07:30 ET | [8-K](/filings/0001213900-26-056227.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-056227 |
## Latest annual report
[Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001628280-26-063506.md), filed Sep 25, 2026.
## Forecast league
Not in this season’s league. [This season’s league](/leagues.md)
## About the filer
- CIK: 1873875
- Tickers: IXHL
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.